AIM Reveals New Positive Data on Ampligen's Anti-Tumor Potential in Combination Therapy

AIM ImmunoTech Inc. (NYSE American: AIM) recently revealed new pre-clinical findings on its drug Ampligen in a combinational therapy for melanoma treatment. The research highlights that combining dendritic cell-based vaccines, anti-PD-L1 checkpoint inhibitors, and Ampligen-induced chemokine modulation can decelerate tumor growth and enhance survival rates in a mouse model.

The study, entitled “Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1,” has been published in the peer-reviewed journal Vaccines. AIM’s Medical Officer, Dr. David Strayer, remarked on the findings, emphasizing that this pre-clinical data underscores Ampligen's therapeutic promise when combined with dendritic-cell vaccines and anti-PD-L1 checkpoint inhibitors, either individually or together. He noted that the data reinforces AIM’s confidence in the continued development of Ampligen as an anti-tumor therapy.

AIM ImmunoTech Inc. specializes in the development and research of therapeutics aimed at treating various types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s flagship product, Ampligen® (rintatolimod), is an investigational drug that acts as a dsRNA and a highly selective TLR3 agonist immuno-modulator. It is currently undergoing clinical trials for its broad-spectrum efficacy in important cancers, viral diseases, and immune system disorders.

The announcement and subsequent publication of this research are significant steps for AIM ImmunoTech as they continue to explore and confirm the potential of Ampligen as a treatment for challenging diseases. The integration of Ampligen with other therapeutic approaches, such as dendritic cell-based vaccines and checkpoint inhibitors, could offer new hope for more effective cancer treatments.